Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Revenio Group share plunges after margin pressure and high debt
Revenio Group reported significant reported sales growth in Q2 following the acquisition of Visionix, while gross margins fell sharply and the organic core business stagnated. Net sales rose to EUR 39.6m, gross margin fell to 64.7%, and net debt increased to EUR 238m (leverage 5.3x adjusted EBITDA). Management reports faster integration and already secured synergies of EUR 5m, but plans a mandatory capital increase of over EUR 80m and expects currency-adjusted revenue of EUR 190–205m in 2026. The stock fell sharply in pre-market trading as investors prioritized profitability pressure and balance-sheet risks over the revenue increase. » More on de.investing.com
Revenio increases revenue in Q3 2025 by 8.1% and improves EBIT
Revenio reports net revenue of €25.9m for Q3 2025 (+8.1%, slightly above analysts' expectations) and an operating profit (EBIT) of €6.0m (+9.1%). Earnings per share were €0.173; for the nine-month period net revenue rose to €78.5m (+7.5%) and EBIT to €18.7m (+17.8%). The balance sheet remains strong with an equity ratio of 79.6% and net gearing of -2.8%. Revenio launches the iCare ALTIUS data platform, sees growth potential in software and AI offerings, and confirms 2025 constant-currency revenue growth guidance of 6–15%, while noting currency headwinds in the Asia-Pacific region and about €2m of FDA-related costs. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 58.8M | 127.03% |
| Gross profit | 15.7M | 38.94% |
| Net profit | 3.4M | 26.09% |
| EBITDA | 8.6M | 19.44% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €267.06M |
Number of shares | 26.71M |
52-week high/low | €22.70 - €10.00 |
| Dividends | No |
Beta | 0.93 |
P/E ratio | 20.97 |
PEG ratio | -0.56 |
P/B ratio | 1.74 |
P/S ratio | 2.49 |
Company profile
Revenio Group Oyj, a health technology company, designs, manufactures, and sells ophthalmic diagnostics and devices for the detection of glaucoma, macular degeneration, diabetic retinopathy, and cataracts in Finland, rest of Europe, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; DRSplus, a device for detection of diabetic retinopathy; iCare MAIA, a microperimeter to measure the visual field; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. It also provides Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
| Name | Revenio Group |
| CEO | Jouni Erik Toijala |
| Headquarters | Vantaa,
Finland |
| Website | |
| IPO | 06/10/2015 |
| Employees | 247 |
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | 0KFH.L |
Hel | REG1V.HE |
Helsinki | REG1V.HE |
Frankfurt | R0V.F |
Düsseldorf | R0V.DU |
London | 0KFH.L |
München | R0V.MU |